(elexacaftor + ivacaftor + tezacaftor) + ivacaftor

all catalysts(0)

nothing on the calendar yet

News(10)

• ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands
  After achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia th…
  biospace · 10d ago
• Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
  Sionna Therapeutics is laying off almost half its workforce as the company recovers from the failure of its closely watched cystic fibrosis add-on program.
  fiercebiotech · 18d ago
• With mRNA back in the spotlight, tRNA shows potential to treat genetic disease
  New research coming out of the University of Toronto has shown that transfer RNA may offer a promising therapeutic avenue for treating genetic diseases.
  fiercebiotech · 1mo ago
• STAT+: Comments on OMB research rule mysteriously removed from federal website
  Some comments on a proposed OMB research rule have been mysteriously removed from a public-facing government webpage.
  stat · 1mo ago
• Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
  Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
  biopharma_dive · 1mo ago
• Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
  A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
  biospace · 1mo ago
• STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
  A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.
  stat · 1mo ago
• Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
  Sionna Therapeutics has axed a cystic fibrosis add-on program after flunking a phase 2 trial, eliminating a would-be challenger to Vertex Pharmaceuticals’ empire. The biotech plans to “take actions…
  fiercebiotech · 1mo ago
• Vertex’s biggest overhang: a rival 50 times smaller
  Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.
  biopharma_dive · 1mo ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 3mo ago